These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators. Than TH, Swethadri GK, Wong J, Ahmad T, Jamil D, Maganlal RK, Hamdi MM, Abdullah MS. Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527 [Abstract] [Full Text] [Related]
23. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M. Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294 [Abstract] [Full Text] [Related]
25. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW. Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553 [Abstract] [Full Text] [Related]
35. Telomerase activity in "suspicious" thyroid cytology. Lerma E, Mora J. Cancer; 2005 Dec 25; 105(6):492-7. PubMed ID: 16104043 [Abstract] [Full Text] [Related]
36. RET and p53 expression in thyroid follicular adenoma: a study of 52 cases with 14 years follow-up. Othman NH, Omar E, Mahmood MH, Madhavan M. Malays J Pathol; 2005 Dec 25; 27(2):91-8. PubMed ID: 17191391 [Abstract] [Full Text] [Related]
37. Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy. Máximo V, Lima J, Soares P, Botelho T, Gomes L, Sobrinho-Simões M. Mitochondrion; 2005 Oct 25; 5(5):333-40. PubMed ID: 16183030 [Abstract] [Full Text] [Related]